On the evening of August 27th, Xingqi Eye Medicine released its semi annual report for 2025. During the reporting period, the company achieved a revenue of 1162742877.58 yuan, an increase of 30.38% compared to the same period last year; The net profit attributable to shareholders of the listed company was 334826054.80 yuan, a significant increase of 97.75% compared to the same period last year.

As a national high-tech enterprise mainly engaged in the subdivision of ophthalmic drugs, the company continues to focus on the ophthalmic field, adhere to the path of professional development, and continuously enhance its industry status and market competitiveness. During the reporting period, the company's management team, under the leadership of the board of directors, focused on the company's development strategy and business goals, consolidated the foundation of early development achievements, deepened resource integration, improved internal management level, actively and orderly promoted and implemented various important work and business plans, and achieved the company's long-term and sustainable development goals. The company adheres to independent research and development, consolidates its core competitive advantages, optimizes its production layout, and expands its sales market.

In terms of production management, the company's production center significantly improves the compatibility of the production line and greatly enhances the stability of packaging line operation through efficient allocation and stable operation of resources, construction and upgrading of workshop projects, and upgrading of new product specifications on the production line; Comprehensively promoting the digital transformation of enterprises, achieving improvements in workflow, work efficiency, and production compliance; Build an energy management system data platform, promote the paperless process of statistical analysis, and improve energy efficiency through technological innovation and management optimization; Significantly improving the utilization rate of water resources, comprehensively maintaining and upgrading the sewage treatment system, enhancing the system's processing capacity and reliability, implementing scientific periodic replacement management of activated carbon in air conditioning systems, optimizing the use of consumables while ensuring air quality, and effectively reducing energy consumption and carbon emissions.

In terms of quality management, the company's quality center actively carries out the upgrading of sterile appendices and CCS (Pollution Control Strategy) projects, fully promoting the implementation of new regulations and the upgrading of the 2025 Pharmacopoeia. At the same time, we will deepen the optimization of the 9000 system and GM management processes, and participate in the construction and verification of new production lines and projects. In terms of responsibility implementation and institutional improvement, we will effectively fulfill the main responsibility of MAH, continuously improve the MAH management system, and actively carry out work related to new variety commissioned production.

In terms of product research and development, the company aims to continuously improve and innovate by developing new products with independent intellectual property rights, and accelerate the comprehensive and differentiated layout of the research and development pipeline. The company attaches great importance to the development of new products and continuously strengthens its research and development efforts in the field of innovative drugs. The R&D center has established a reasonable and comprehensive drug R&D quality management system, and actively cooperates closely with multiple domestic and foreign research institutes and universities. Establish a research and development model that focuses on independent innovation and is supplemented by industry university research joint development. Realize steady improvement and continuous improvement in research and development management. Relying on sharp industry foresight, years of accumulated experience in eye medicine research and development, a stable and reliable R&D team, and advanced R&D equipment, the company has achieved a series of results in R&D and has strong technical achievement transformation capabilities. During the reporting period, the company achieved fruitful results in product research and development: the company's application for voriconazole eye drops has now obtained a Phase I clinical research report; Tafluoroprost eye drops have obtained the Drug Registration Certificate issued by the National Medical Products Administration; Phase III clinical trial of lidocaine hydrochloride ophthalmic gel has started. As of June 2025, the SQ-22031 eye drops declared by the company have obtained Phase I clinical research reports and started Phase II clinical trials for the treatment of neurotrophic keratitis. This product is a Class 1 therapeutic biological product, intended for clinical use in dry eye syndrome and neurotrophic keratitis. Neurotrophic keratitis was included in the second batch of rare disease catalogs in China in 2023.

In terms of marketing expansion, the company adheres to the marketing policy of "healthy operation, collaborative win-win, and leading development", with Chinese ophthalmic disease patients as the center, meeting clinical treatment needs as the starting point, continuously improving the ability to understand and meet customer needs, expectations, and preferences, establishing good customer relationships, and aiming for customer satisfaction. It continues to leverage the deep cultivation advantages of ophthalmic drugs for many years, vigorously promotes the new development of omnichannel marketing models, achieves greater market coverage, and continuously enhances brand influence and reputation. In 2025, the company actively promotes the construction of a three-level network for myopia prevention and control, and collaborates with the National Eye Disease Clinical Center to advance the China Myopia Prevention and Control Capability Building Alliance, promoting standardized diagnosis and treatment of myopia prevention and control in children. The company's professional surgical promotion team actively promotes market access and standardized medication, providing innovative and universal solutions for the management of long-term chronic myopia in children and adolescents in China.

From the perspective of market environment, the global ophthalmic drug market shows stable growth and high concentration, while the Chinese ophthalmic drug market has vast space and enormous development potential. With the improvement of medical testing methods and the continuous increase in people's requirements for disease treatment, ophthalmic drug products are showing a trend of "differentiation". The dosage forms of ophthalmic drugs have gradually increased from single eye drops to gel preparations, sustained-release preparations, nano preparations and other dosage forms, showing a diversified development trend.

In recent years, under the influence of multiple factors such as aging population, increasing work and study pressure, excessive use of electronic products, and improper use of eyes, the number of ophthalmic diagnosis and treatment patients in China has continued to rise, and patients with different ophthalmic diseases have appeared in various age groups. Among them, the adolescent population is mainly affected by myopia and other diseases. According to data released by the National Bureau of Disease Control and Prevention, the overall myopia rate among children and adolescents in China in 2022 was 51.9%, including 14.5% for 6-year-old children, 36% for primary school students, 71.6% for junior high school students, and 81% for high school students; The middle-aged and young population mainly suffer from diseases such as dry eye syndrome and optic neuritis; The middle-aged and elderly population mainly suffer from diseases such as cataracts, glaucoma, and dry eye syndrome. At the same time, national policies are increasingly emphasizing eye health, and the future market downturn will add impetus to the development of the ophthalmology industry. The market size will continue to expand, and the company's future development prospects are broad.